# US 2014/0228417 A1 · Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0228417 A1
- Document ID: US20140228417A1
- Status: Published application
- Kind: A1
- Application number: 14/349,983
- Filed: 2012-01-23
- Published: 2014-08-14
- Earliest claimed: 2011-10-05
- Assignees: Mapi Pharma Ltd.
- Inventors: Michael Mizhiritskii; Ehud Marom; Shai Rubnov
- Web page: https://patentgrep.com/patent/US20140228417A1

## CPC

- C07D 275/03: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61K 31/426: 1,3-Thiazoles
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to processes and intermediates for the preparation of derivatives of 2-arylthiazole such as Febuxostat and its analogs. Febuxostat which is an inhibitor of xanthine oxidase, is used for the treatment of chronic hyperuricaemia in conditions in which urate deposition has occurred, such as gouty arthritis.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A process for the preparation of Febuxostat represented by the structure of formula (1):
the process comprising the steps of:
(a) coupling a thiazole carboxylic acid derivative of formula (III):
with an aryl derivative of formula (II)
to form a 2-arylthiazolcarboxylic acid derivative of formula (IV):
wherein
R1 is methyl and R2 is isobutyl;
R is H or Si(Ra)3 wherein each Ra is independently of the other an unsubstituted or substituted alkyl, arylalkyl or aryl;
X, Y and Z are as described in (i) or (ii) hereinbelow:
(i) X is Hal or OSO2R′ wherein R′ is an unsubstituted or substituted alkyl, alkylaryl or aryl, Z is absent and Y is B(OR″)2 wherein R″ is H or an unsubstituted or substituted alkyl or aryl; or
(ii) X is absent, Z together with the nitrogen to which is attached forms an N-oxide moiety of the formula ⊕N—O⊖; and Y is Hal or OSO2R′ wherein R′ is as defined above;
(b) when Z together with the nitrogen to which is attached forms an N-oxide, reducing the compound of formula (IV); and
(c) optionally, when R is Si(Ra)3, converting the resultant compound of step (a) or (b) to Febuxostat of formula (1).

### Claim 25 (depends on 24)

The process according to claim 24, wherein X is a Hal or OSO2R′, Z is absent and Y is B(OR″)2 wherein R′ and R″ are as defined above, and the process comprises the following steps:
(a) coupling a thiazole carboxylic acid derivative of formula (3)
with an aryl boronic acid derivative of formula (2)
so as to generate a 2-arylthiazolcarboxylic acid derivative of formula (4);
and
(b) optionally, when R is Si(Ra)3, converting the 2-arylthiazolcarboxylic acid silyl ester of formula (4) to Febuxostat of formula (1).

### Claim 26 (depends on 25)

The process according to claim 25, wherein step (a) is conducted in the presence of a base and a palladium catalyst at a temperature of about RT to reflux in a solvent.

### Claim 27 (depends on 26)

The process according to claim 26, wherein the base is an inorganic or organic base selected from sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, sodium ethoxide, potassium tert-butoxide, sodium methoxide, potassium fluoride and cesium fluoride.

### Claim 28 (depends on 25)

The process according to claim 25, wherein step (a) is conducted in the presence of an ionic liquid and a palladium catalyst.

### Claim 29 (depends on 28)

The process according to claim 28, wherein the ionic liquid is [BMIM][BF4]).

### Claim 30 (depends on 26)

The process according to claim 26, wherein the palladium catalyst is tetrakis(triphenylphosphine)palladium, dichlorobis(triphenylphosphine)palladium, or 1,1′-bis(diphenylphosphino)ferrocene palladium chloride.

### Claim 31 (depends on 24)

The process according to claim 24, wherein R is H.

### Claim 32 (depends on 24)

The process according to claim 24, wherein R is Si(Ra)3.

### Claim 33 (depends on 24)

The process according to claim 24, wherein R is selected from the group consisting of trialkylsilyl, triarylsilyl, dialkylaryl silyl, or diarylalkyl silyl.

### Claim 34 (depends on 33)

The process according to claim 33, wherein R is selected from the group consisting of trimethylsilyl (TMS), triethylsilyl (TES), tripropylsilyl, triisopropylsilyl, triphenylsilyl, di-t-butyldimethyl silyl (TBDMS) and tert-butyldiphenylsilyl (TBDPS).

### Claim 35 (depends on 24)

The process according to claim 24, wherein in step (a) the arylboronic acid of formula (II) or (2) is 3-cyano-4-isobutoxyphenylboronic acid.

### Claim 36 (depends on 24)

The process according to claim 24, wherein in step (a) the 2-X-thiazole carboxylic acid of formula (III) or (3) is 2-bromo-4-methylthiazole-5-carboxylic acid.

### Claim 37 (depends on 24)

The process according to claim 24, wherein X is absent, Z together with the nitrogen to which is attached form an N-oxide moiety of the formula: ⊕N—O⊖; and Y is Hal or OSO2R′ wherein R′ is as defined above, and the process comprises the following steps:
(a) coupling a thiazole carboxylic acid N-oxide of formula (7):
with an aryl derivative of formula (5)
wherein R is as defined above so as to generate a 2-arylthiazolcarboxylic acid derivative of formula (8):
(b) reducing the compound of formula (8) to a 2-arylthiazolcarboxylic acid derivative of formula (4);
and
(c) optionally, when R is Si(Ra)3, converting the 2-arylthiazolcarboxylic acid silyl ester of formula (4) to Febuxostat of formula (1).

### Claim 38 (depends on 37)

The process according to claim 37, wherein the N-oxide derivative of formula (7) is prepared by oxidizing a thiazole-5-carboxylic acid derivative of formula:
using an oxygen transfer agent.

### Claim 39 (depends on 38)

The process according to claim 38, wherein the oxygen transfer agent is a hydrogen peroxide-urea complex in the presence of a carboxylic acid anhydride, and the reaction is carried out in an organic solvent at a temperature range of about 0°-60° C.

### Claim 40 (depends on 37)

The process according to claim 37, wherein in step (a) the reaction is carried out in the presence of an organometallic catalyst and a ligand in an organic solvent in the presence of a pivalic acid salt.

### Claim 41 (depends on 40)

The process according to claim 40, wherein the organometallic catalyst is palladium acetate and the ligand is 2-(diphenylphosphino-2′-(N,N dimethylamino) biphenyl.

### Claim 42 (depends on 37)

The process according to claim 37, wherein in step (b) the reduction reagent is selected from the group consisting of ammonium formate/Pd/C, iron dust in acetic acid, and zinc dust/ammonium chloride in water and a water miscible solvent.

### Claim 43 (depends on 24)

The process according to claim 24, wherein R is Si(Ra)3, and the conversion step comprises hydrolyzing the silyl ester group CO2Si(Ra)3 to a carboxylic acid CO2H.

### Claim 44 (depends on 24)

The process according to claim 24,
wherein X in compound (III) is selected from the group consisting of Cl, Br, I, OMs, OTs and OTf; or
wherein Y in compound (II) is selected from the group consisting of Cl, Br, I, OMs, OTs and OTf; or
wherein Y in compound (II) is B(OR″)2, wherein R″ is H.

### Claim 45 (depends on 24)

Febuxostat of formula I, which is prepared by the process according to claim 24.

### Claim 46 (depends on 24)

A method of treating hyperuricaemia comprising administering to a subject in need thereof an effective amount of Febuxostat which is prepared in accordance with the process of claim 24.
